Cargando…

Immune Profile of BRAF-Mutated Metastatic Colorectal Tumors with Good Prognosis after Palliative Chemotherapy

SIMPLE SUMMARY: The present study demonstrated that the distinct subgroup of BRAF-MT CRC showed a good response after palliative chemotherapy. Based on the immune profile analysis, higher PD-L1 expression and CD8-positive cell infiltration were shown in this study population. Furthermore, the assess...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jeong Eun, Kim, Ji-Hun, Kim, Sang-Yeob, Cho, Hyungwoo, Ryu, Yeon-Mi, Hong, Yong Sang, Kim, Sun Young, Kim, Tae Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139363/ https://www.ncbi.nlm.nih.gov/pubmed/35625987 http://dx.doi.org/10.3390/cancers14102383

Ejemplares similares

Comprehensive evaluation of the tumor immune microenvironment and its dynamic changes in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy: From the phase II ADORE study
por: Cho, Hyungwoo, et al.
Publicado: (2022)

Usefulness of Carcinoembryonic Antigen for Monitoring Tumor Progression during Palliative Chemotherapy in Metastatic Colorectal Cancer
por: Kim, Gangmi, et al.
Publicado: (2013)

Dynamic increase of M2 macrophages is associated with disease progression of colorectal cancers following cetuximab-based treatment
por: Kim, Hyung-Don, et al.
Publicado: (2022)

Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer
por: Baek, Sun Kyung, et al.
Publicado: (2019)

Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer
por: Kim, Sang-A, et al.
Publicado: (2021)

Clinicogenomic Characteristics and Treatment of Young-Onset Colorectal Cancer Patients Treated With Palliative Therapy in Real-World Practice
por: Jeong, Hyehyun, et al.
Publicado: (2022)

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma()()
por: Kim, Hee Kyung, et al.
Publicado: (2016)

Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index
por: Choi, Younak, et al.
Publicado: (2015)

Colorectal Cancer Prognosis Is Not Associated with BRAF and KRAS Mutations-A STROBE Compliant Study
por: Lee, Joon-Hyop, et al.
Publicado: (2019)

Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
por: Kwon, Yujin, et al.
Publicado: (2017)

CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
por: Kang, Sora, et al.
Publicado: (2023)

SIRT1 Expression Is Associated with Good Prognosis in Colorectal Cancer
por: Jung, Wonkyung, et al.
Publicado: (2013)

Prognostic factors for renal function deterioration during palliative first-line chemotherapy for metastatic colorectal cancer: a retrospective study
por: Lim, Ah Reum, et al.
Publicado: (2022)

Early venous thromboembolism at the beginning of palliative chemotherapy is a poor prognostic factor in patients with metastatic pancreatic cancer: a retrospective study
por: Kim, Jung Sun, et al.
Publicado: (2018)

Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
por: Kim, Jwa Hoon, et al.
Publicado: (2022)

BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options
por: Hummel, Michael, et al.
Publicado: (2021)

The beneficial effect of palliative resection in metastatic colorectal cancer
por: Park, J H, et al.
Publicado: (2013)

Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with Advanced Colorectal Cancer
por: Kim, Jee Hyun, et al.
Publicado: (2005)

Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer
por: Lee, Jii Bum, et al.
Publicado: (2021)

A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair–Deficient/Microsatellite Instability–High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer
por: Kim, Jwa Hoon, et al.
Publicado: (2020)

PHLPP1 Overexpression was Associated With a Good Prognosis With Decreased AKT Activity in Gastric Cancer
por: Park, Sun Yi, et al.
Publicado: (2022)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021)

Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer
por: Hwang, Jun-Eul, et al.
Publicado: (2011)

Validation of the Prognosis in Palliative Care Study Predictor Models in Terminal Cancer Patients
por: Kim, Eun-Shin, et al.
Publicado: (2014)

Hepatic resection after neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer: need for cautious planning
por: Kim, Young Il, et al.
Publicado: (2019)

The Impact of Palliative Chemotherapy on the Survival of Patients With Metastatic Colorectal Cancer in Jordan
por: Alkader, Mohammad S, et al.
Publicado: (2023)

Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer
por: LIM, SUNG HEE, et al.
Publicado: (2023)

p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer
por: Kim, Se Hyun, et al.
Publicado: (2016)

Impact of palliative therapies in metastatic esophageal cancer patients not receiving chemotherapy
por: Kim, Sungjin, et al.
Publicado: (2020)

Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
por: Kim, Dalyong, et al.
Publicado: (2017)

Paired Primary and Metastatic Tumor Analysis of Somatic Mutations in Synchronous and Metachronous Colorectal Cancer
por: Kim, Kyu-pyo, et al.
Publicado: (2017)

Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy
por: Cho, Kyoung-Min, et al.
Publicado: (2017)

Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma
por: Wu, Xiaowen, et al.
Publicado: (2017)

Impact of Hyperglycemia on Survival and Infection-Related Adverse Events in Patients with Metastatic Colorectal Cancer Who Were Receiving Palliative Chemotherapy
por: Hong, Yong Joo, et al.
Publicado: (2014)

Palliative radiotherapy in patients with a symptomatic pelvic mass of metastatic colorectal cancer
por: Bae, Sun Hyun, et al.
Publicado: (2011)

Metastatic Spermatic Cord Tumor From Colorectal Cancer
por: Jang, Ji Geon, et al.
Publicado: (2015)

A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
por: Kim, Youjin, et al.
Publicado: (2019)

Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer
por: Kim, Sun Young, et al.
Publicado: (2020)

Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype
por: Yi, Seong Yoon, et al.
Publicado: (2010)

Prognostic implications of regression of metastatic axillary lymph nodes after neoadjuvant chemotherapy in patients with breast cancer
por: Chung, Yul Ri, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_49s2ssseouqalpjnp4gf82rppf